ERBB2 and neoplasm: Since glypican-3 (GPC3), mesothelin (MSLN), and HER2 are commonly used markers for tumor detection and/or as potential therapeutic targets, and a growing number of studies have confirmed the efficacy of specific CAR-T targeting them has achieved considerable achievements in the immunotherapy of solid tumors [11, 12, 22, 23].